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Uterine fibroids are the most common benign pelvic tumor of the female genital tract and tend to increase with age; they cause
menorrhagia, dysmenorrhea, pelvic pressure symptoms, back pain, and subfertility. Currently, the management is based mainly on
medical or surgical approaches. The nonsurgical and minimally invasive therapies are emerging approaches that to the state of the
art include uterine artery embolization (UAE), image-guided thermal ablation techniques like magnetic resonance-guided focused
ultrasound surgery (MRgFUS) or radiofrequency ablation (RF), and percutaneous microwave ablation (PMWA). The purpose of
the present review is to describe feasibility results and safety of PMWA according to largest studies available in current literature.
Moreover technical aspects of the procedure were analyzed providing important data on large scale about potential efficacy of
PMWA in clinical setting. However larger studies with international registries and randomized, prospective trials are still needed
to better demonstrate the expanding benefits of PMWA in the management of uterine fibroids.
1. Introduction
Uterine fibroids (leiomyomas) are the most common benign
pelvic tumors in reproductive age group women. It occurs in
approximately 20–40% of women in this age group and about
a quarter among themwill have significant clinical symptoms,
such as menorrhagia, dysmenorrhea, pelvic pressure symp-
toms, back pain, subfertility, and reduced quality of life [1–3].
Uterine fibroids are categorized by their location in the
uterus as intramural (entirely or mostly contained within the
myometrium), submucosal (projecting into the endometrial
cavity and may also be pedunculated), or subserosal (pro-
jecting outward from the serosal surface of uterus and may
be pedunculated). Uterine fibroids are estrogen-dependent
and they can enlarge during pregnancy or with the use of
oral contraceptive pills and shrink after menopause. Fibroids
can be subject to a wide variety of degenerative phenomena,
especially during rapid growth including myxoid, hyaline,
cystic, red (hemorrhagic), and fatty degeneration as well
as calcification and necrosis. These all contribute to the
complexity and variability of fibroid imaging appearance.
Currently, the management options included are medical
(hormonal and nonhormonal), nonsurgical, and surgical
(myomectomy and hysterectomy) [4–6].
Thenonsurgical andminimally invasive therapies include
uterine artery embolization (UAE) [7, 8] and image-guided
thermal ablation techniques: magnetic resonance-guided
focused ultrasound surgery (MRgFUS) [9–11], radiofrequency
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ablation (RF) [12], and percutaneous microwave ablation
(PMWA) [13, 14].
According to reported literature, UAE involves occlusion
of uterine arteries bilaterally using particulate emboli result-
ing in ischemic necrosis of the fibroid.This decrease in fibroid
volume leads to symptomatic relief. Common concerns
with UAE include postprocedural pain, postembolization
syndrome, and risk of infection. Rarer complications include
premature ovarian failure and endometrial atrophy.
Patient satisfaction rate following UAE when compared
with the surgical modality is similar at 2- and 5-year interval.
UAE was associated with higher need for surgical interven-
tion (between 15 and 32%) after 2 years [20].
MRgFUS uses a high-intensity ultrasound beam to
increase the local temperature of the targeted tissue leading
to necrosis and destruction of the tissue. The magnetic
resonance is used for planning and controlling the ablative
process, restricting it mainly to the selected tissue, thereby
avoiding damage to adjacent structures. MRgFUS appears to
be safe and an effective modality for treating symptomatic
fibroids [9].
In a study that evaluates clinical outcomes after session of
MRgFUS for uterine fibroids, a total of 109 results measured
by the symptom severity score (SSS) were greater than
predicted, with subjects having a mean decrease of 39% and
36% at 6 and 12 months, respectively [9].
Some of the minor complications include skin burns,
abdominal wall oedema, and febrile morbidity. Serious com-
plications, such as deep vein thrombosis, bowel injury, per-
sistent neuropathies, and need for emergency hysterectomies,
have been reported.
The major limitation of MRgFUS currently is that many
women are not eligible for the procedure because of the bowel
interposition between ultrasound beam and fibroid or other
reasons like more than five fibroids, size or shape of fibroids,
or presence of adenomyosis. Furthermore, the treatment
of large fibroids with MRgFUS is a long time procedure.
Also the cost effectiveness of MRgFUS is still under debate.
First-line treatment of eligible women with MRI-guided
focused ultrasound is a cost-effective noninvasive strategy.
For those not eligible for MRI-guided focused ultrasound,
UAE remains a cost-effective option [21].
The radiofrequency ablation was done laparoscopically
and found to be safe and efficacious; recently the transvaginal
approach has been introduced to deliver the energy [22, 23].
Ablation with microwave has several intrinsic advantages
over RFA, including the capability to generate very high tissue
temperature, less intraprocedural pain, larger coagulation
zones, less sensitivity to tissue type and charring, improved
performance near blood vessels, and no requirement of
ground pads [24].
Ultrasound (US) guided percutaneous microwave abla-
tion (PMWA) is minimally invasive, has low time require-
ments, is easy to perform, and has been broadly used for the
treatments of solid tumors in organs other than the uterus
with favourable effects.
The purpose of the present review is to describe feasibility
and safety of the PMWA of uterine fibroids. Moreover, we
analyzed technical aspects of the procedure, results, and
effectiveness.
2. Materials and Methods
2.1. Study Selection. A systematic literature search was per-
formed using the PubMed databases for studies published
in the English language from January 2005 to March 2017,
with the syntax interventional radiology, percutaneous ther-
mal ablation, percutaneous microwave ablation (or MWA),
uterine fibroid, and symptomatic uterine fibroid.
Only articles that described percutaneous ablation with
microwave in uterine fibroids were included.
We identified additional studies through manual search
of the primary studies references, review articles, and key
journals.
We excluded papers that included data reported previ-
ously.
The following variables were extracted, where available,
from the included articles: number of patients; dimension
of the fibroids treated; technology used; number of antenna
placements and total time of ablation, volume of ablation,
and sessions of treatments; technical and clinical success;
complications; follow-up; second treatment; surgery (yes or
not).
The primary endpoint was to investigate feasibility and
safety of the technique. The secondary endpoint was to
evaluate effectiveness in terms of improvement of symptoms
and quality of life (QOL) and reduction in volume of the
uterine myomas.
In Table 1, data extrapolated from the studies analyzed
were described.
The feasibility was defined as technical success rate, in
particular as the correct positioning of the antennas within
the fibroid using sovrapubic US as imaging guidance.
Clinical success was evaluated thorough clinical evalu-
ation, which included the symptoms severity score of the
Uterine Fibroids and the Quality of Life questionnaire [25].
All papers reported complications; they were classified
according to the Common Terminology Criteria for Adverse
Events (CTCAE) classification [26].
Safety was evaluated on the basis of the complications
that were recorded immediately after the procedure and
during the follow-up [27]. A complication was defined as
“immediate” when it occurred up to 6–24 h following the
procedure, as “periprocedural” if it occurred within 30 days,
and as “delayed” if it occurred more than 30 days after
the procedure [27]. Major complications were defined as
complications that, if untreated, might threaten the patient’s
life, lead to substantial morbidity and disability, result in
hospital admission, or substantially lengthen the patient’s
hospital stay [26, 28]. Minor complications included typical
postablation syndrome symptoms (fever, pain, nausea, and
vomiting) if present > 4 days after the ablation procedure.
Complications were further divided into two causal cate-
gories: those secondary to theMWantenna placement (bowel
perforation, infection, and bleeding) and those secondary to
thermal injury (damage to adjacent organs) [26].
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(a) (b) (c)
Figure 1: T2wMRI axial (a) and sagittal (b) images show an intramuralmyoma; T1W-FSMRaxial image confirmed awell capsulated centrally
hyalinized uterine lesion (c).
2.2. Technical Aspects. During PWMA, the antennas are
accurately inserted into the fibroid using ultrasound trans-
abdominal guidance, and the microwave generator located in
the front of the ablation electrode emits an electromagnetic
wavewith a frequency of 2450MHz, as indicated in all studies
[13, 15–18] except Liu et al. [19].The power ranged from 50W
to 100W in the studies reported, when the information is
available.
When reported (Table 1) one antenna was used if the
maximum diameter of the fibroid is less than 5 cm; otherwise
2 antennas were deployed. Not all authors reported ablation
time.
2.3. Pretreatment and Clinical Aspects. In all patients [13, 15–
19] uterine fibroids have been diagnosed using ultrasonogra-
phy (transvaginal and/or sovrapubic) and contrast-enhanced
MRI (CE-MRI) (Figures 1(a), 1(b), and 1(c)); in some studies
before treatment biopsy was performed [13].
The aim of the pretreatment imaging evaluation is to
determine the number, dimensions, and location of the
myomas.
In all studies [13, 15–19, 29] the mean diameter and
volume of the fibroids were calculated according to retro-
spective formulas (length +width + height)/3 and 4/3𝜋(𝑑/2)3
before and after the ablation via CEUS (contrast-enhanced
ultrasonography) or MRI.
In all studies [13, 15–19] indications or inclusion criteria
are similar. In particular, uterine fibroids are symptomatic in
all cases (pain,menorrhagia, anemia, and urinary frequency);
they are not responsive to medication or other conservative
treatment, and women present a strong desire to preserve
uterus, and they do not use hormonal drugs usually within
the first 3 months of ablation; exclusion criteria comprise
desire of future pregnancy, malignant neoplasms of any
organ; acute pelvic inflammation; and severe coagulation
disorder.
In the studies reporting symptomatic aspects (Table 1)
patients underwent a thorough clinical evaluation, which
included the symptom severity score of the Uterine Fibroids
Symptom and Quality of Life questionnaire [25]. The ques-
tionnaire consists of eight questions addressing the frequency
and severity of symptoms and 29 questions on health-related
quality of life (QOL). Two distinct scores were calculated
for symptom severity and QOL. Higher symptom scores
are indicative of greater symptom severity, and higher QOL
scores indicate a better health-related QOL.
2.4. Posttreatment Evaluation. The evaluation of diameter
and volume reduction and the changes in symptom score
and in health-related QOL represent the criteria reported to
evaluate effectiveness of the procedure. Clinical evaluation
was performed every 3 months after treatment.
Moreover in some studies, clinical success in terms of
severity of symptoms was based on hemoglobin (Hb) levels
measured before and after ablation procedures and after every
3 months (Table 1).
On the basis of available data (Table 1), contrast-enhanced
US (CEUS) is usually performed immediately after the
procedure and/or the day after to evaluate the volume of
ablation (Figures 2(a), 2(b), and 2(c)). CE-MRI and/or CEUS
are used during follow-up to evaluate the shrinkage of the
lesion.
3. Results
All the results are summarized in Table 1.
In a total of six articles [13, 15–19] the overall experience
of percutaneous microwave ablation of fibroids was reported.
A total of 541 patients with 647 fibroids were treated. The
studywith the highest number of treated fibroids was recently
published by Liu et al. (311 patients and 405 leiomyomas) with
a size ranging between 2.6 and 10 centimeters.
As reported above, a single antenna was usually used
for ablation; in large fibroids (>5 cm) authors decided to use
double antenna; this decision depends also on differentMWA
generators available. All generators considered were based on
a 2450Mhz ablation frequency with a power ranging from
50 to 100W. In particular, according to power and ablation
6 BioMed Research International
(a) (b)
(c)
Figure 2: B-mode sovrapubic ultrasound image shows the myoma and the planned path for the insertion of antenna (a); B-mode sovrapubic
ultrasound image shows the antenna correctly positioned within the myoma (b); CEUS performed the day after the procedure reveals the
desired volume of ablation within the myoma (c).
expected volumes, one antenna was applied for fibroids with
a diameter < 5 cm and double antennas were applied for
fibroids with diameter > 5 cm [18], with ablation time ranging
between 300 and 600 seconds. Zhang et al. [13, 15] used single
antenna and an ablation time of 300 s and 490 s, respectively.
The gauge diameter of each antenna ranged between 15 and 16
based on available equipment, with length ranging between
18 cm and 20 cm (Table 1). Zhang et al. [13] used to fill the
bladder with saline prior each ablation, to optimize fibroid
position and put them near abdominal wall obtaining at the
same time a better visualization of uterus and bladder itself in
order to reduce possible damage during ablation procedure.
In all considered studies (Table 1) a technical success of 100%
was reportedwith awhole ablated volumepercentage equal to
100% for fibroids that were <5 cm in diameter, when ablated
with a single antenna.
Clinical success in terms of volume reduction rate was
from 15,9% to 93.1% (Table 1). This wide range of variability
depends on the different time of instrumental follow-up
(immediately after procedure and after 6 months).
In the series analyzed, only Liu et al. [19] reported a twice
treatment in 2 patients with more than 10 fibroids to ensure
that the ablation was successful with an overall reduction rate
in their series of 86.7% at 12 months.
Different results were obtained according different
follow-up examinations performed at different time points
using Contrast-Enhanced Ultrasound (CEUS) or Contrast-
EnhancedMagnetic Resonance Imaging (CE-MRI) with best
shrinkage rate of 93.1% (range 61.8–93.1%) reached by Zhang
et al. after 12 months [13].
Studies in which clinical success was evaluated in terms
of Hb levels measured before and after ablation procedures
showed an interesting improvement in Hb level (Table 1)
(from 88,64 g/l to 123,21 g/l at 3 months), when considered
as a part of clinical success [17, 19].
Clinical success in terms of improvement of the quality of
life (QOL) or health-related quality of life (HROL) measured
using the Uterine Fibroids Symptom and Quality of Life
(UFS-QOL) questionnaire reached normal level at twelfth
month according to Yang et al. results [17], or a significant
improvement in scores (𝑝 value < 0.05%) after treatment,
according to Liu et al. data [19].
No major complications were observed, as those requir-
ing further interventions and/or hospitalization, according
CommonTerminology Criteria for Adverse Events (CTCAE)
[26].
Minor complications were observed, in particular lower
abdominal pain, with a 4/5-point scale value in 7 patients
and 2/5 in 3 patients, in Yang et al. series [17]. A frequent
reported data was discharge of bloody fluids for no more
than 20 days and fragments of necrotic tissues from vagina
in multiple cases. These phenomena were judged normally
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and frequently observed in all series, particularly in those of
Zhang et al. [13, 17–19]; they considered quite normal side
effects due to endometrial inflammation and irritation caused
by necrotizing liquefaction following ablation treatments.
On the basis of the data reported (Table 1), we can hypoth-
esize that a surgical revision (myomectomy or hysterectomy)
as a consequence of the ablation procedure or as failure of
the percutaneous ablation and consequent persistence of the
symptoms was never necessary, but this information is not
reported in any study.
4. Discussion
Currently, in situ ablation techniques have enabled a great
advancement in conservative treatments of uterine myomas
[13, 20, 30, 31]. When compared with other thermal ablation
techniques, microwaves ablations achieve higher intratu-
moral temperatures and larger ablations zone [32].
In this review, we found that PMWA of medium-sized
and large uterine myomas alone is a feasible and safe proce-
dure that has good short-term follow-up results.
Microwave ablation is less expensive thanMRgFUS, easy,
and efficient procedure that can be repeated in the same
session or at a later time [13]. Microwave generators are
widely available in many hospitals for other tumor ablation
therapies, and the equipment is simple to use. Larger areas of
necrosis (up to 6 cm in diameter) can be achieved in a single
access with a single antenna than can be achieved with other
thermal ablative tools, particularly laser fibers andmonopolar
and bipolar needles.The advantage of using a single insertion
is reduction of the risk of injury and adhesions [29, 33].
Uterine fibroids are benign lesions, so the main purpose
of the treatment is to relieve clinical symptoms and improve
patient quality of life. Partial ablation in particular in a
relatively unsafe position such as close to bowel or bladder is
enough to obtain good clinical results. From a technical point
of view injection of saline solution among the bowel loops
could be useful in some cases [33].
In our institution, we use a single antenna and we
withdraw or reinsert it within the myoma for another session
of ablation with the only aim to create a volume of abla-
tion contained in the myoma respecting safety margins, as
described by Zhang et al. [13]: during the ablation, variations
in the echo from the fibroid were monitored by real-time
ultrasonography. Moreover, the reduction of the volume of
the myomas seems to be related to the sarcoid percentage of
the lesion; for example, Liu et al. [19] reported a slightly lower
reduction of volume after 12 months related to intramural
leiomyomas [18].
The use of CEUS has the advantage of precise targeting
within highly vascularized areas. CEUS depicts changes in
tissue echotexture during the procedure and the presence of
residual viable tissue, which is useful for assessing the success
of the procedure. CEUS can be used in follow-up to predict
clinical failure or recurrence. In our experience, CEUS has
been a readily available and reliable tool for fast evaluation of
residual vascularization [29].
Microwave ablation has a low rate of complications,
as reported in this review. In our study, we found no
major complications, including bleeding. Bleeding can be
successfully prevented by the use of a track ablation technique
(cauterization of the needle tract at the end of the ablation)
to coagulate perimyoma vessels along the access path: we
always used this technique and we suppose that is a common
technical practice but in the studies reported it is not
specified.
None reported data about the risk of adhesions, but we
suppose that none is able to evaluate the rate of adhesion
because none of the patients needed second-look laparo-
scopic or abdominal surgery. Adhesions are instead a con-
solidated risk with laparoscopic and conventional surgical
approaches [34].
In literature only a comparative study between PMWA
and USgHIFU is present [18]; authors showed that treatment
time was shorter in the PMWA group compared to the
USgHIFUgroup (median treatment timewas 46.2min versus
92.5min, resp.), producing a larger zone of ablation in a
shorter amount of time. The primary reason for this differ-
ence in results is likely related to the principle mechanism
of action of the two therapy methods. The fibroid ablation
rate, average regression rate, and drop in SSS at 6months after
treatment were similar between the two groups, respectively
USgHIFU (77.1 ± 18.2%, 50.3% and 9.4) and PMWA (79.8 ±
14.9%, 52.4% and 10.2).
Both therapies did not require general anesthesia and
usually only one night of hospitalization is required for
PMWA.
UAE is performed under conscious sedation, spinal/
epidural, and sometimes general anesthesia; common con-
cerns with UAE include postprocedural pain, postemboliza-
tion syndrome and risk of infection [35]. This procedure is
less endured by patients comparedwith ablative techniques in
terms of intra- and postprocedural pain and risk of infections
[35].
The effect of this minimally invasive procedures on
fertility is debatable [35]: nowadays no established data are
available even if Kim et al. [36] reported 3 cases of uncompli-
cated pregnancies in 69 patients treated with radiofrequency
ablation. Ovarian reserve appears to be affected by UAE in
premenopausal women [37].
HIFU seems to preserve ovarian reserve more than the
above-mentioned procedures but data available are only
preliminary [38].
5. Conclusions
Currently multiple treatment options are available for uterine
fibroids.
The choice of treatment depends largely on a variety of
factors related to patient, operator, and center considered.
No randomized studies exist to compare treatments.
In conclusion, the current study demonstrates the
feasibility, safety, and potential efficacy of percutaneous
microwave ablation of uterine fibroids.
The specific role of PMWA in the management of uter-
ine fibroids may be considered under investigation. Larger
studies with the help of international registries and ideally
large, randomized, prospective trials are much needed to
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better demonstrate the benefits of thermal ablation therapies
in themanagement of uterine fibroids and to help operator to
choose a technique compared to another.
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